fda drug shortage list semaglutide status january 2025 GLP-1 = Over US judge upholds FDA's removal
Description
Early Phase 2 trial data suggests this triple mechanism produces the most aggressive weight loss of any pharmaceutical approach to date, with some dose groups achieving over 24% body weight reduction in 48 weeks
Rare but serious complications associated with GLP-1 receptor agonists include pancreatitis, which can occur regardless of gallbladder status
Why isnt it medication alone in the Calibrate program
Acute pancreatitis has been observed with the group of GLP-1 receptor agonist medications like semaglutide
Individuals with uncontrolled hypertension, cardiovascular disease, or hyperthyroidism should avoid phentermine
